Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy protocol developed by Guangzhou University of Traditional Chinese Medicine for the treatment of acute ischemic stroke. This integrated clinical pathway, evaluated in the PAIS (Clinical Pathway for Acute Ischemic Stroke) Phase 4 trial (NCT00966316), combines conventional Western medicine—specifically aspirin—with Traditional Chinese Medicine (TCM) components, including individualized or standardized Chinese herbal formulations and acupuncture. The protocol is designed to improve clinical outcomes, reduce the length of hospital stays, and lower treatment costs by utilizing the antiplatelet effects of aspirin alongside the multi-target, holistic approach of TCM, which typically aims for neuroprotection and improved cerebral blood flow. The specific herbal formulations used are part of a comprehensive treatment protocol rather than a single named pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + Chinese herbs (Guangzhou University of Chinese Medicine).